Plant Name: Rhododendron mucronulatum
Taxonomic Information:
Plant ID: NPO17759
Plant Latin Name: Rhododendron mucronulatum
Taxonomy Genus: Rhododendron
Taxonomy Family: Ericaceae
Plant External Links:
NCBI TaxonomyDB:
105903
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; China; RussiaTraditional Medicine System:
TCMGeographical Distribution:
South Korea; China; Russia
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR5A; DRD1; HCAR2; HTR2B; HTR1A; HTR6; | |
| TDP1; CDA; NOX4; APEX1; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; | |
| MMP2; MMP9; | |
| CREBBP; | |
| F3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.148E-15 | 1.121E-10 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.112E-12 | 5.162E-08 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.928E-11 | 1.341E-07 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.928E-11 | 1.341E-07 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.333E-10 | 8.577E-07 | CA1, CA12, CA2, CA7, CA9 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 4.141E-10 | 8.577E-07 | HTR1A, HTR2B, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.125E-09 | 6.975E-06 | HTR1A, HTR5A, HTR7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.204E-07 | 1.456E-04 | CA1, CA12, CA2, CA7, CA9, CDA, CREBBP, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 1.238E-06 | 1.172E-03 | CDA, MAPK1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.712E-06 | 3.233E-03 | CA2, CA7 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 4.596E-06 | 3.787E-03 | HTR1A, HTR2B, HTR7 |
| MF | Unclassified; | GO:0004871; signal transducer activity | 7.069E-06 | 4.833E-03 | CREBBP, DRD1, F3, HCAR2, HTR1A, HTR2B, HTR5A, HTR6, HTR7, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.081E-05 | 6.041E-03 | APEX1, CA2, CA9, DRD1, HTR5A, MAPK1, NOX4 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.082E-05 | 6.041E-03 | DRD1, HTR1A, HTR2B, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.852E-05 | 8.768E-03 | CA1, CA2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.032E-14 | 1.207E-12 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.868E-09 | 1.093E-07 | HTR6, HTR7, HTR1A, HTR2B, MAPK1, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 5.880E-08 | 2.293E-06 | HCAR2, CREBBP, HTR6, HTR1A, MAPK1, DRD1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 4.141E-07 | 1.211E-05 | HTR6, HTR7, HTR1A, HTR2B, DRD1, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.299E-06 | 3.040E-05 | HTR6, HTR7, HTR2B, DRD1, HTR5A |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.199E-05 | 2.337E-04 | MMP2, MAPK1, MMP9 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.795E-04 | 2.334E-03 | MMP2, MAPK1, F3 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.692E-04 | 2.334E-03 | MMP2, MAPK1, MMP9 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.193E-04 | 1.994E-03 | HTR2B, MAPK1, DRD1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.425E-04 | 8.962E-03 | CREBBP, MMP2, MAPK1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.301E-04 | 6.202E-03 | CREBBP, MAPK1, MMP9 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; HTR1A; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MMP9; MAPK1; MMP2; CA1; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MAPK1; CDA; MMP2; CA9; |
| NA: NA | Social phobia | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; HCAR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HCAR2; HTR1A; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; HTR1A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR1A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; HTR6; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2B; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; HTR1A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; |
| NA: NA | Episode | NA | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; HTR1A; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR6; HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; HTR1A; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
